<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176669</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2010-03</org_study_id>
    <nct_id>NCT01176669</nct_id>
  </id_info>
  <brief_title>Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients</brief_title>
  <official_title>A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Metastatic Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this clinical research study is to discover if the study drug apatinib can&#xD;
      shrink or slow the growth of pretreated metastatic triple-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor&#xD;
      (VEGFR), and its anti-angiogenesis effect has been viewed in preclinical tests. The&#xD;
      investigators' phase I study has shown that the drug's toxicity is manageable and the maximum&#xD;
      tolerable daily dose is 850 mg. The hypothesis of this clinical research study is to discover&#xD;
      if the study drug apatinib can shrink or slow the growth of triple-negative breast cancer.&#xD;
      The safety of apatinib will also be studied. Patients physical state, symptoms, changes in&#xD;
      the size of the tumor, and laboratory findings obtained while on-study will help the research&#xD;
      team decide if apatinib is safe and effective in pretreated metastatic triple-negative breast&#xD;
      cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DCR(Disease control rate) for IIa</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS(Progression free survival) for IIb</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS(Progression free survival) for IIa</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall survival)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective response rate)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL (Quality of life)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR(Disease control rate) for IIb</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.</description>
    <arm_group_label>Apatinib</arm_group_label>
    <other_name>Target therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Women diagnosed with triple negative breast cancer (breast cancer is estrogen receptor&#xD;
             negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth&#xD;
             factor receptor negative (HER2-). HER2- is defined as 0 or 1+ staining on&#xD;
             immunohistochemistry or FISH/CISH negative for gene amplification.&#xD;
&#xD;
          -  Metastatic breast cancer, confirmed by histological analysis.&#xD;
&#xD;
          -  Have failed for at least one chemotherapy regimen, but at most three&#xD;
             regimens(including adjuvant and neo-adjuvant setting).&#xD;
&#xD;
          -  Duration from the last therapy (chemotherapy, radiotherapy, target therapy and&#xD;
             operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).&#xD;
&#xD;
          -  Have at least one extracranial measurable site of disease according to RECIST 1.1&#xD;
             criteria that has not been previously irradiated. If the patient has had previous&#xD;
             radiation to the marker lesion(s), there must be evidence of disease progression since&#xD;
             the radiation.&#xD;
&#xD;
          -  Life expectancy of more than 3 months.&#xD;
&#xD;
          -  If the patients have brain or meninges metastases, the lesions must have been&#xD;
             controlled at least 8 weeks.&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 9.0g/dl,&#xD;
             neutrophils ≥ 1.5×10^9/L, platelets ≥ 80×10^9/L , ALT ≤ 2.5 x upper limit of normal&#xD;
             (ULN), AST ≤ 2.5 x ULN, serum bilirubin ≤ 1.5 x ULN, serum creatine ≤ 1.5 x ULN,&#xD;
             creatinine clearance rate ≥ 50ml/min, PT, APTT, TT, Fbg normal).&#xD;
&#xD;
          -  Written informed consent prior to study specific screening procedures, with the&#xD;
             understanding that the patient has the right to withdraw from the study at any time&#xD;
             without prejudice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial.&#xD;
&#xD;
          -  Have any severe and/or uncontrolled medical conditions or other conditions that could&#xD;
             affect their participation in the study such as: Congestive heart failure: New York&#xD;
             Heart Association Class III/IV, Unstable angina pectoris, symptomatic congestive heart&#xD;
             failure, myocardial infarction within 6 months of start of study drug, serious&#xD;
             uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.&#xD;
&#xD;
          -  Any factors that influence the usage of oral administration.&#xD;
&#xD;
          -  Receiving the therapy of thrombolysis or anticoagulation.&#xD;
&#xD;
          -  Unhealed wound or bone fracture.&#xD;
&#xD;
          -  Urine protein ≥++ and confirmed &gt;1.0 g by the 24h quantity.&#xD;
&#xD;
          -  Previous or present history of pulmonary fibrosis,interstitial&#xD;
             pneumonia,pneumoconiosis,radiation pneumonitis,drug-related pneumonitis or&#xD;
             greatly-impaired pulmonary function.&#xD;
&#xD;
          -  Disability of serious uncontrolled intercurrence infection.&#xD;
&#xD;
          -  Abuse of alcohol or drugs.&#xD;
&#xD;
          -  Have received prior treatment with a VEGFR, PDGFR or s-SRC TKI (Bevacizumab is&#xD;
             permitted).&#xD;
&#xD;
          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma&#xD;
             in-situ of uterine cervix.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, Doctorship</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Apatinib</keyword>
  <keyword>Triple-Negative Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>ER/PR Negative</keyword>
  <keyword>Her2/Neu Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

